Ernexa Therapeutics Inc. (ERNA)
Automate Your Wheel Strategy on ERNA
With Tiblio's Option Bot, you can configure your own wheel strategy including ERNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ERNA
- Rev/Share 0.0942
- Book/Share 0.8581
- PB 1.3402
- Debt/Equity 0.1334
- CurrentRatio 1.8076
- ROIC -1.8993
- MktCap 8813943.0
- FreeCF/Share -2.7893
- PFCF -0.6101
- PE -0.1363
- Debt/Assets 0.0782
- DivYield 0
- ROE 3.8685
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentation to highlight preclinical data from the company's lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials Presentation to highlight preclinical data from the company's lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials
Read More
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference , being held September 8–10, 2025.
Read More
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”
Read More
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Published: May 08, 2025 by: Newsfile Corp
Sentiment: Neutral
Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Read More
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28.
Read More
Ernexa Therapeutics Closes New Funding Round
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer
Read More
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs
Read More
About Ernexa Therapeutics Inc. (ERNA)
- IPO Date 1991-08-29
- Website https://www.ernexatx.com
- Industry Biotechnology
- CEO Sanjeev Luther
- Employees 6